euro-gastro-2018-scientifictracks

11 / 25

6 t h A n n u a l E u r o p e a n C o n f e r e n c e o n
Gastroenterology
Euro Gastro 2018
J u n e 1 9 - 2 0 , 2 0 1 8
P a r i s , F r a n c e
Page 33
Journal of Clinical Gastroenterology and Hepatology
ISSN 2575-7733
The most widely prescribed regimen for first-line H. pylori eradication has
been a triple therapy with proton pump inhibitor (PPI) and 2 antibiotics.
However, the eradication rate of PPI-based regimen has been declining over
the years, mainly due to resistance to antibiotics. To exert sufficient H. pylori
killing effect of antibiotics, maintenance of intragastric pH around 6 to 7 is
mandatory. Development of potent gastric acid secretion-lowering agents
should improve the eradication rate. Potassium-competitive acid blocker
(PCAB) possess approximately 350 times more potent inhibitory effects
than typical PPIs, works immediately, and the effect lasts for a long time.
Additionally, metabolic elimination is independent of cytochrome P450 (CYP)
2C19 polymorphism, which is distinct from PPI. This new agent is expected to
offer clinical advantages over conventional PPI-based eradication therapies.
Biography
John Ignatius G Ledesma is the head of the GI Endoscopy
unit of Riverside Medical Center, Bacolod City, Philippines. He
completed his Postgraduate training at the Makati Medical
Center where he was awarded the most outstanding intern and
most outstanding chief resident. He was the Chief of fellows
and by far the only Research Fellow in Gastroenterology. He
has been a speaker in over 250 local, national and international
scientific meetings. He is the recipient of over a dozen awards
of distinction, recognition, achievement, services and most
recently, The Canlaon Medical Society most outstanding
Physician of 2017.
Management of Helicobacter pyloriin the era of potassium-
competitive acid blocker
John Ignatius G Ledesma
Riverside Medical Center, Philippines
John Ignatius, J Clin Gastroenterol Hepatol 2018, Volume: 2
DOI: 10.21767/2575-7733-C1-002